Detailed data from a Phase 2b/3 study of Merck’s treatment clesrovimab should support the company’s efforts to win approval ...

Kineta, Inc. (OTC Pink: KANT) , a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that its ...

While you may think of healthcare as only covering human health, animal and pet health is also a growing sector. Click to read.

Merck’s investigational antibody clesrovimab demonstrated more than 60% effectiveness in reducing some types of respiratory ...

Merck announces positive results from Phase 2b/3 and interim Phase 3 trials of a monoclonal antibody designed to protect infants from RSV.

Trodelvy’s next big readout is EVOKE-03, which is testing the Gilead drug with Merck’s PD-1 inhibitor Keytruda in PD-L1-high ...

Behind negative returns for shares of American Express and Merck, the Dow Jones Industrial Average is declining Friday morning.

New data released by Merck suggests AstraZeneca and Sanofi’s Beyfortus, the monoclonal antibody injection that protects ...

In the study, clesrovimab (MK-1654) significantly reduced the incidence of RSV disease and hospitalisations in healthy ...

Interim phase 3 results showed the IL-13 monoclonal antibody improves histology and symptoms in EoE, even in participants ...

Merck Foundation in partnership with African First Ladies and Ministries of Health and Medical Societies provided out of total 2080 Scholarships, 830 Scholarships of one-year Post-Graduate Diploma and ...

From manufacturing vital drugs to driving research to raising funds and awareness, leaders like AstraZeneca, Ford and Estée Lauder are having an impact ...